Logo-brb

Biomedical Research Bulletin

Biomed Res Bull. 2023;1(4): 141-147.
doi: 10.34172/biomedrb.2023.27
  Abstract View: 240
  PDF Download: 111

Review Article

Effects of Sacituzumab on Breast Cancer: Target Therapy

Elina Armani Khatibi 1 ORCID logo, Tooba Gholikhani 1,2* ORCID logo, Balam Jimenez Brito 3, Nastaran Farshbaf Moghimi 4

1 Student Research Committee, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
2 Nanora Pharmaceuticals Ltd, Tabriz, Iran
3 Victoria University of Wellington, School of Biological Sciences, Wellington, New Zealand
4 Department of Pharmaceutics, School of Pharmacy, Ardabil University of Medical Science, Ardabil, Iran
*Corresponding Author: Tooba Gholikhani, Email: tooba.souldouz@gmail.com

Abstract

Triple-negative breast cancer (TNBC) is considered one of the most aggressive forms of BC, which increases the risk of cancer-associated death. Despite the availability of specifically targeted medications for treating TNBC with HER2-positive or hormone receptor-positive cancers, chemotherapy is still the mainstay of treatment. Sacituzumab, an antibody-drug conjugate (ADC), targets tumor-associated calcium signal transducer 2 (Trop-2)-expressing cells and presents biologically active metabolites of irinotecan hydrochloride (SN-38). This review evaluates the effectiveness and safety of Sacituzumab in treating metastatic or previously treated TNBC in patients. According to the National Center for Biotechnology Information website, another epithelial metastasis has been included in data on clinical trials and sacituzumab. Sacituzumab has hopeful antitumor effects on patients with metastatic TNBC treated with at least two treatment lines, according to a clinical trial that is in phase I/II. Sacituzumab has a controllable adverse effect, with neutropenia, nausea, and diarrhea being the most frequent negative side effects. As a result of these promising early efficacy data, Sacituzumab’s activity may develop in TNBC, as well as various other epithelial tumors, such as hormone receptor-positive BC.
First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 241

Your browser does not support the canvas element.


PDF Download: 111

Your browser does not support the canvas element.

Submitted: 30 Nov 2023
Accepted: 15 Dec 2023
ePublished: 29 Dec 2023
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)